Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma


| Source: Bristol Myers Squibb

In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant improvement in recurrence-free survival compared to placebo

CheckMate -76K marks the fifth Opdivo-based indication in earlier stages of cancer, in the U.S.

Opdivo is the only PD-1 inhibitor that is indicated as an adjuvant treatment for eligible patients with stages IIB, IIC, III, as well as stage IV completely resected melanoma